Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16ClNO2S.C6H6O3S |
Molecular Weight | 479.997 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC=C1.COC(=O)[C@@H](N2CCC3=C(C2)C=CS3)C4=CC=CC=C4Cl
InChI
InChIKey=CUZIJKLLBDXNFV-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.C6H6O3S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;7-10(8,9)6-4-2-1-3-5-6/h2-5,7,9,15H,6,8,10H2,1H3;1-5H,(H,7,8,9)/t15-;/m0./s1
Molecular Formula | C16H16ClNO2S |
Molecular Weight | 321.822 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C6H6O3S |
Molecular Weight | 158.175 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct
inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that
inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet
aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active
metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet
aggregation induced by agonists other than ADP is also inhibited by blocking the amplification
of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
6.9 null [pKi] | |||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia.
Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7972479E11 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7963841E11 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7972479E11 |
|||
Preventing | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7972479E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1500 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15800 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2520 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4600 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.521 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3130 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50600 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7440 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
9890 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.767 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
1.09 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, unknown |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Other AEs: Uric acid abnormal... |
1650 mg single, oral Overdose Dose: 1650 mg Route: oral Route: single Dose: 1650 mg Co-administed with:: phenytoin sodium(1400 mg; single) Sources: simvastatin(120 mg; single) |
unknown, 49 years n = 1 Health Status: unknown Age Group: 49 years Sex: M Population Size: 1 Sources: |
|
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Disc. AE: Transaminases increased, Fever... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Fever (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Uric acid abnormal | 5 patients | 600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Fever | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Transaminases increased | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Future perspectives for optimizing oral antiplatelet therapy. | 2001 |
|
Atherothrombosis: a major health burden. | 2001 |
|
The use of antiplatelet agents in acute cardiac care. | 2001 Apr |
|
Antithrombotic drugs for secondary stroke prophylaxis. | 2001 Apr |
|
Clopidogrel in invasive management of non-ST-elevation ACS. | 2001 Aug 18 |
|
Bench to bedside: the development of rapamycin and its application to stent restenosis. | 2001 Aug 21 |
|
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. | 2001 Feb |
|
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. | 2001 Feb 1 |
|
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. | 2001 Feb 15 |
|
Extensive thrombus prior to elective percutaneous coronary intervention. | 2001 Jul |
|
Diffuse alveolar hemorrhage after clopidogrel use. | 2001 Jul |
|
The P2Y12 receptor as a therapeutic target in cardiovascular disease. | 2001 Jun |
|
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study]. | 2001 Mar 29 |
|
What is the optimal medical management of ischemic heart failure? | 2001 Mar-Apr |
|
Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). | 2001 May 15 |
|
Prospective controlled study of carotid endarterectomy with hemashield patch: is it thrombogenic? | 2001 May-Jun |
|
Antiplatelet agents for secondary prevention of ischemic stroke. | 2001 Oct |
|
Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review. | 2001 Sep |
|
Adjunctive therapies in the cath lab. Subacute stent thrombosis developing twelve days after discontinuation of ticlopidine treatment. | 2001 Sep |
|
Endovascular brachytherapy for prophylaxis against restenosis after long-segment femoropopliteal placement of stents: initial results. | 2001 Sep |
Sample Use Guides
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
The recommended daily dose of is 75 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10077233
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:05:09 UTC 2023
by
admin
on
Fri Dec 15 18:05:09 UTC 2023
|
Record UNII |
BL9VGG8BHW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CLOPIDOGRAL HEXAL (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A-PHARMA (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN:
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
744256-69-7
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
PRIMARY | |||
|
DBSALT002628
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
PRIMARY | |||
|
SUB30714
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
PRIMARY | |||
|
BL9VGG8BHW
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
PRIMARY | |||
|
100000115443
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
PRIMARY | |||
|
9847991
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
PRIMARY | |||
|
DTXSID30225441
Created by
admin on Fri Dec 15 18:05:09 UTC 2023 , Edited by admin on Fri Dec 15 18:05:09 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |